ASKA Pharmaceutical Holdings (4886) · FactFirst stated
Revenue and profit growth, but a decline in interim net income, for the cumulative consolidated second quarter of FY2026
First written in FY2027-H1. . Latest entry: FY2027-H1.
1entries
1years
0from disclosures
How it moved
Same theme, other companies
Coexistence of higher revenue and profit with a decline in net income attributable to the parent companyA theme 142 companies write about · 33 as a headwind · 19 as a tailwind
23 other companies' latest entry also says "First stated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 142 companies compared. The sentences above are computed from all 142.